Efficacy and safety of risankizumab in patients with erythrodermic and sub-erythrodermic psoriasis: a case series

Erythrodermic psoriasis (EP) is a severe and complex form of psoriasis. While risankizumab, an interleukin (IL)-23 inhibitor, has demonstrated efficacy in patients with moderate-to-severe plaque psoriasis, its effectiveness in patients with EP remains less explored. The literature contains several...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Andrea D'Arino, Maria Concetta Fargnoli, Pasquale Frascione, Chiara Assorgi, Annunziata Dattola, Viviana Lora, Matteo Megna, Flavia Pigliacelli, Emanuele Vagnozzi, Diego Orsini
Format:	Artigo
Sprog:	Inglês
Udgivet:	PAGEPress Publications 2025-07-01
Serier:	Dermatology Reports
Fag:	Psoriasis risankizumab erythrodermic psoriasis safety efficacy
Online adgang:	https://www.pagepress.org/journals/dr/article/view/10379
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!